Overview

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Status:
Completed
Trial end date:
2017-07-08
Target enrollment:
Participant gender:
Summary
E7080-A001-010 is a multicenter, parallel-group study in participants with mild, moderate, or severe hepatic or renal impairment and age-, gender-, and smoking status-matched healthy participants. The primary objective of the study is to obtain plasma from participants for use in in vitro protein binding studies.
Phase:
Early Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Lenvatinib